Injections de lymphocytes du donneur (DLI) : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

De Vos, John; BAUDOUX, Etienne; Bay, Jacques-Olivier; Calmels, Boris; Cras, Audrey; El Cheikh, Jean; Guerout-Verite, Marie-Agnès; Lacassagne, Marie-Noëlle; Lamure, Sylvain; Letellier, Catherine; Menard, Anne-Lise; Daguindau, Etienne; Poiré, Xavier; Yakoub-Agha, Ibrahim; Guillaume, Thierry

doi:10.1016/j.bulcan.2018.10.002

Article (Scientific journals)

Injections de lymphocytes du donneur (DLI) : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

De Vos, John; BAUDOUX, Etienne; Bay, Jacques-Olivier et al.

2019 • In Bulletin du Cancer, 106, p. 35-S39

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/231692

DOI
10.1016/j.bulcan.2018.10.002

PubMed
30580911

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Injections de lymphocytes du donneur DLI-recommandations de la SFGMTC.pdf

Author preprint (279.34 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Injection de lymphocytes du donneur; Immunothérapie cellulaire; Allogreffe de cellules souches hématopoïétiques; Donor lymphocyte infusion; Cellular immunotherapy; Allogeneic stem cell transplantation

Abstract :

[fr] Les injections de lymphocytes du donneur (DLI) peuvent être proposées pour traiter ou prévenir la rechute d’une hémopathie maligne après allogreffe de cellules souches hématopoïétiques. L’efficacité est principalement rapportée dans le traitement de la leucémie myéloïde chronique et les lymphomes à caractère indolent. L’activité antitumorale est moindre pour les leucémies aiguës et les syndromes myélodysplasiques. L’effet bénéfique « greffon versus leucémie » (GVL) doit toujours être évalué par rapport à la morbi-mortalité possible liée à la réaction du greffon contre l’hôte (GVHD). Les premières recommandations de la SFGM-TC de 2013 concernant l’utilisation des DLI sont mises à jour. Les doses de DLI dans le cadre des greffes haplo-identiques sont indiquées. L’excédent de cellules souches périphériques mobilisées par rhG-CSF peut être utilisé comme DLI. La définition et la place des DLI préemptives et prophylactiques sont précisées. Des recommandations sont également proposées concernant l’évaluation de la qualité des DLI décongelées et le suivi clinique et biologique après DLI.
[en] Donor lymphocyte infusion (DLI) can be proposed to treat or prevent the relapse of malignant hemopathies following allogeneic stem cell transplantation. The efficiency has been mainly reported in the treatment of CML and low-grade lymphomas while the anti-tumoral activity is less in forms of acute leukemia and myelodysplastic syndromes. The GVL benefit should always be compared to the possible toxic effects of GVHD. This article updates the initial SFGM-TC recommendations, proposed in 2013, that were focused on the use of DLI. Doses of DLI in the context of haplo-identical stem cell transplantation are now indicated. We confirm that remaining mobilized stem cells may be used as classical DLI. The definition and the place of preemptive and prophylactic DLI are precisely given. Recommendations regarding the quality of thawed DLI as well as necessary clinical and biological follow-up are also described in detail.

Disciplines :

Hematology

Author, co-author :

De Vos, John

BAUDOUX, Etienne ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Laboratoire de thérapie cellulaire et génique (LTCG)

Bay, Jacques-Olivier

Calmels, Boris

Cras, Audrey

El Cheikh, Jean

Guerout-Verite, Marie-Agnès

Lacassagne, Marie-Noëlle

Lamure, Sylvain

Letellier, Catherine

More authors (5 more)

Language :

French

Title :

Injections de lymphocytes du donneur (DLI) : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)

Alternative titles :

[en] Donor Lymphocyte Infusions (DLI): Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

Publication date :

December 2019

Journal title :

Bulletin du Cancer

ISSN :

0007-4551

eISSN :

1769-6917

Publisher :

Elsevier, Netherlands

Volume :

106

Pages :

S35-S39

Peer reviewed :

Peer Reviewed verified by ORBi

Additional URL :

https://doi.org/10.1016/j.bulcan.2018.10.002

Available on ORBi :

since 17 January 2019

Statistics

Number of views

212 (10 by ULiège)

Number of downloads

6 (5 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Kolb, H.-J., Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112:12 (2008), 4371–4383.
Castagna, L., Sarina, B., Bramanti, S., Perseghin, P., Mariotti, J., Morabito, L., Donor lymphocyte infusion after allogeneic stem cell transplantation. Transfus Apher Sci 54:3 (2016), 345–355.
Schmid, C., Labopin, M., Nagler, A., Bornhäuser, M., Finke, J., Fassas, A., et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 25:31 (2007), 4938–4945.
Benjamin, J.E., Gill, S., Negrin, R.S., Biology and clinical effects of natural killer cells in allogeneic transplantation. Curr Opin Oncol 22:2 (2010), 130–137.
Guillaume, T., Porcheron, S., Audat, F., Bancillon, N., Berceanu, A., Charbonnier, A., et al. Prophylactic, preemptive and curative use of donor lymphocyte infusion in patients undergoing allogeneic stem cell transplantation: guidelines of the SFGM-TC. Pathol Biol (Paris) 62:4 (2014), 193–196.
Tipton, R., Yakoub-Agha, I., How we harmonize HSCT clinical practices among the SFGM-TC centers. Bull Cancer (Paris) 103:11 (2016), S193–S197.
Kongtim, P., Lee, D.A., Cooper, L.J.N., Kebriaei, P., Champlin, R.E., Ciurea, S.O., Haploidentical hematopoietic stem cell transplantation as a platform for post-transplantation cellular therapy. Biol Blood Marrow Transplant 21:10 (2015), 1714–1720.
Ghiso, A., Raiola, A.M., Gualandi, F., Dominietto, A., Varaldo, R., Van Lint, M.T., et al. DLI after haploidentical BMT with post-transplant CY. Bone Marrow Transplant 50:1 (2015), 56–61.
Zeidan, A.M., Forde, P.M., Symons, H., Chen, A., Smith, B.D., Pratz, K., et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant J 20:3 (2014), 314–318.
Goldsmith, S.R., Slade, M., DiPersio, J.F., Westervelt, P., Schroeder, M.A., Gao, F., et al. Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy. Bone Marrow Transplant 52:12 (2017), 1623–1628.
Tsirigotis, P., Byrne, M., Schmid, C., Baron, F., Ciceri, F., Esteve, J., et al. Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplant 51:11 (2016), 1431–1438.
Legrand, F., Le Floch, A.-C., Granata, A., Fürst, S., Faucher, C., Lemarie, C., et al. Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML. Bone Marrow Transplant 52:4 (2017), 620–621.
Shanavas, M., Messner, H.A., Kamel-Reid, S., Atenafu, E.G., Gupta, V., Kuruvilla, J., et al. A comparison of long-term outcomes of donor lymphocyte infusions and tyrosine kinase inhibitors in patients with relapsed CML after allogeneic hematopoietic cell transplantation. Clin Lymphoma Myeloma Leuk 14:1 (2014), 87–92.
El-Cheikh, J., Crocchiolo, R., Furst, S., Ladaique, P., Castagna, L., Faucher, C., et al. Lenalidomide plus donor-lymphocytes infusion after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with high-risk multiple myeloma. Exp Hematol 40:7 (2012), 521–527.
Tsirigotis, P., Danylesko, I., Gkirkas, K., Shem-Tov, N., Yerushalmi, R., Stamouli, M., et al. Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 51:10 (2016), 1313–1317.
El-Cheikh, J., Crocchiolo, R., Furst, S., Ladaique, P., Castagna, L., Faucher, C., et al. Donor CD3(+) lymphocyte infusion after reduced intensity conditioning allogeneic stem cell transplantation: single-center experience. Exp Hematol 41:1 (2013), 17–27.
Bar, M., Sandmaier, B.M., Inamoto, Y., Bruno, B., Hari, P., Chauncey, T., et al. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant 19:6 (2013), 949–957.
Radujkovic, A., Guglielmi, C., Bergantini, S., Iacobelli, S., van Biezen, A., Milojkovic, D., et al. Donor lymphocyte infusions for chronic myeloid leukemia relapsing after allogeneic stem cell transplantation: may we predict graft-versus-leukemia without graft-versus-host disease?. Biol Blood Marrow Transplant 21:7 (2015), 1230–1236.
Solomon, S.R., Sizemore, C.A., Zhang, X., Brown, S., Holland, H.K., Morris, L.E., et al. Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial. Bone Marrow Transplant 49:5 (2014), 616–621.
Bruno, B., Thibert, J.-B., Bancillon, N., Desbos, A., Fawaz, A., Fournier, I., et al. Information and consent forms for hematopoietic stem cell transplantation donors and recipients: guidelines from the Franchophone society of bone marrow transplantation and cellular therapy (SFGM-TC). Bull Cancer (Paris) 103:11 (2016), S198–S200.
Calmels, B., Boulanger, F., Baudoux, E., Decot, V., Fawaz, A., Giraud, C., et al. Conservation and destruction of autologous and allogeneic cryopreserved cellular products: recommendations from the SFGM-TC. Pathol Biol (Paris) 62:4 (2014), 221–225.
Huang, X.-J., Liu, D.-H., Liu, K.-Y., Xu, L.-P., Chen, Y.-H., Wang, Y., et al. Modified donor lymphocyte infusion after HLA-mismatched/haploidentical T cell-replete hematopoietic stem cell transplantation for prophylaxis of relapse of leukemia in patients with advanced leukemia. J Clin Immunol 28:3 (2008), 276–283.
Hasskarl, J., Zerweck, A., Wäsch, R., Ihorst, G., Bertz, H., Finke, J., Induction of graft versus malignancy effect after unrelated allogeneic PBSCT using donor lymphocyte infusions derived from frozen aliquots of the original graft. Bone Marrow Transplant 47:2 (2012), 277–282.
Hossain, N.M., Klumpp, T., Ulicny, J., Garner, M., Kropf, P.L., Mangan, K.F., et al. Donor lymphocyte infusion in hematologic malignancies – Good to be fresh?. Clin Lymphoma Myeloma Leuk 16:2 (2016), 111–115.
Abbi, K.K.S., Zhu, J., Ehmann, W.C., Epner, E., Carraher, M., Mierski, J., et al. G-CSF mobilized vs conventional donor lymphocytes for therapy of relapse or incomplete engraftment after allogeneic hematopoietic transplantation. Bone Marrow Transplant 48:3 (2013), 357–362.